TY - JOUR
T1 - The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients?
AU - Hindryckx, Pieter
AU - Hindryckx, Pieter
AU - Casteele, Niels Vande
AU - Casteele, Niels Vande
AU - Novak, Gregor
AU - Novak, Gregor
AU - Khanna, Reena
AU - Khanna, Reena
AU - D'Haens, Geert
AU - D'Haens, Geert
AU - Sandborn, William J.
AU - Sandborn, William J.
AU - Danese, Silvio
AU - Jairath, Vipul
AU - Jairath, Vipul
AU - Jairath, Vipul
AU - Feagana, Brian G.
AU - Feagana, Brian G.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - © 2017 European Crohn's and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. The therapeutic landscape for inflammatory bowel disease [IBD] is rapidly evolving. Two new biologic drugs, vedolizumab and ustekinumab, have recently entered the marketplace, the first biosimilars have been introduced, and several other agents are at an advanced stage of clinical development. In parallel, therapeutic goals have shifted from symptom control towards mucosal healing and prevention of bowel damage. In the coming years, gastroenterologists will be faced with unprecedented choices when selecting the best treatment for their patients with IBD. In this article, we review existing data on the mechanisms of action, efficacy, and safety of recently approved and late-stage pipeline therapies, and use this information to speculate on the positioning of these drugs, alone or in combination, in therapeutic algorithms for Crohn's disease and ulcerative colitis.
AB - © 2017 European Crohn's and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. The therapeutic landscape for inflammatory bowel disease [IBD] is rapidly evolving. Two new biologic drugs, vedolizumab and ustekinumab, have recently entered the marketplace, the first biosimilars have been introduced, and several other agents are at an advanced stage of clinical development. In parallel, therapeutic goals have shifted from symptom control towards mucosal healing and prevention of bowel damage. In the coming years, gastroenterologists will be faced with unprecedented choices when selecting the best treatment for their patients with IBD. In this article, we review existing data on the mechanisms of action, efficacy, and safety of recently approved and late-stage pipeline therapies, and use this information to speculate on the positioning of these drugs, alone or in combination, in therapeutic algorithms for Crohn's disease and ulcerative colitis.
KW - IL-23 antagonists
KW - Inflammatory bowel disease
KW - JAK inhibitors
KW - Pipeline
KW - Smad7
KW - Sphingosine-1 phosphate
KW - Therapy
KW - TNF antagonists
UR - http://www.scopus.com/inward/record.url?scp=85040635889&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040635889&partnerID=8YFLogxK
U2 - 10.1093/ecco-jcc/jjx117
DO - 10.1093/ecco-jcc/jjx117
M3 - Review article
AN - SCOPUS:85040635889
VL - 12
SP - 105
EP - 109
JO - Journal of Crohn's and Colitis
JF - Journal of Crohn's and Colitis
SN - 1873-9946
IS - 1
ER -